Results 21 to 30 of about 2,286,378 (300)
Trk Receptor Expression and Inhibition in Neuroblastomas [PDF]
Clinical Cancer Research, 2009 Abstract Neuroblastoma, the most common and deadly solid tumor in children, exhibits heterogeneous clinical behavior, from spontaneous regression to relentless progression. Current evidence suggests that the TRK family of neurotrophin receptors plays a critical role in these diverse behaviors.
G. Brodeur +8 more
semanticscholar +4 more sources
Psychopharmacology, 2023 Major depressive disorder (MDD) is defined as a complex mental disorder which is characterized by a pervasive low mood and aversion to activity. Several types of neurotransmitter systems e.g.
N. Madjid +6 more
semanticscholar +1 more source
TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs
Pharmaceuticals, 2021 Recently, two tropomycin receptor kinase (Trk) inhibitors, larotrectinib and entrectinib, have been approved for Trk fusion-positive cancer patients. Clinical trials for larotrectinib and entrectinib were performed with patients selected based on the ...
Sun-Young Han
doaj +1 more source
Cell Communication and Signaling, 2021 Background Neurotrophins can activate multiple signalling pathways in neuronal cells through binding to their cognate receptors, leading to neurotrophic processes such as cell survival and differentiation.
Anja Pišlar, Janko Kos
doaj +1 more source
Activation of Trk neurotrophin receptors in the absence of neurotrophins [PDF]
Proceedings of the National Academy of Sciences, 2001 Neurotrophins regulate neuronal cell survival and synaptic plasticity through activation of Trk receptor tyrosine kinases. Binding of neurotrophins to Trk receptors results in receptor autophosphorylation and downstream phosphorylation cascades.
Francis S. Lee, Moses V. Chao
openalex +4 more sources
Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer
Clinical Cancer Research, 2021 Chromosomal rearrangements of NTRK1–3 resulting in gene fusions (NTRK gene fusions) have been clinically validated as oncogenic drivers in a wide range of human cancers. Typically, NTRK gene fusions involve both inter- and intrachromosomal fusions of the
T. Laetsch, D. Hong
semanticscholar +1 more source
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients
Current Oncology, 2021 Neurotrophic tyrosine receptor kinase gene fusions (NTRK) are oncogenic drivers present at a low frequency in most tumour types (80%) in a small number of rare tumours (e.g., infantile fibrosarcoma [IFS]) and considered mutually exclusive with other ...
Sébastien Perreault +10 more
doaj +1 more source
Molecules, 2022 The tropomyosin receptor kinases (TRKs) have been validated as effective targets in anticancer drug discovery. Two first-generation TRK inhibitors have been approved into market and displayed an encouraging therapeutic response in cancer patients ...
Jie Wang +11 more
doaj +1 more source
The Research Progress of Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusions and Tropomyosin Receptor Kinase (TRK) Inhibitors: A Narrative Review [PDF]
Iran J Public HealthLi J, Liang Y.
europepmc +2 more sources
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults
Current Oncology, 2021 The tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib were recently approved in Canada for the treatment of solid tumours harbouring neurotrophic tyrosine receptor kinase (NTRK) gene fusions.
D. Gwyn Bebb +17 more
doaj +1 more source